CHZ868, a type II JAK2 inhibitor, reverses type I JAK inhibitor persistence and demonstrates efficacy in myeloproliferative neoplasms Journal Article


Authors: Meyer, S.; Keller, M.; Chiu, S.; Koppikar, P.; Guryanova, O.; Rapaport, F.; Xu, K.; Manova, K.; Pankov, D.; O'reilly, R.; Kleppe, M.; Mckenney, A.; Shih, A.; Shank, K.; Ahn, J.; Papalexi, E.; Spitzer, B.; Socci, N.; Viale, A.; Mandon, E.; Ebel, N.; Andraos, R.; Rubert, J.; Dammassa, E.; Romanet, V.; Dölemeyer, A.; Zender, M.; Heinlein, M.; Rampal, R.; Weinberg, R.; Hoffman, R.; Sellers, W.; Hofmann, F.; Murakami, M.; Baffert, F.; Gaul, C.; Radimerski, T.; Levine, R.
Article Title: CHZ868, a type II JAK2 inhibitor, reverses type I JAK inhibitor persistence and demonstrates efficacy in myeloproliferative neoplasms
Abstract: Although clinically tested JAK inhibitors reduce splenomegaly and systemic symptoms, molecular responses are not observed in most myeloproliferative neoplasm (MPN) patients. We previously demonstrated that MPN cells become persistent to type I JAK inhibitors that bind the active conformation of JAK2. We investigated whether CHZ868, a type II JAK inhibitor, would demonstrate activity in JAK inhibitor persistent cells,murine MPN models, and MPN patient samples. JAK2 and MPL mutant cell lines were sensitive to CHZ868, including type I JAK inhibitor persistent cells. CHZ868 showed significant activity in murine MPN models and induced reductions in mutant allele burden not observed with type I JAK inhibitors. These data demonstrate that type II JAK inhibition is a viable therapeutic approach for MPN patients. © 2015 Elsevier Inc.
Keywords: controlled study; myelofibrosis; unclassified drug; drug efficacy; nonhuman; animal cell; mouse; allele; enzyme inhibition; animal experiment; animal model; enzyme phosphorylation; drug mechanism; murinae; myeloproliferative neoplasm; polycythemia vera; janus kinase 2 inhibitor; momelotinib; ruxolitinib; priority journal; article; fedratinib; chz 868; n,n dicyclopropyl 4 [(1,5 dimethyl 1h pyrazol 3 yl)amino] 6 ethyl 1,6 dihydro 1 methylimidazo[4,5 d]pyrrolo[2,3 b]pyridine 7 carboxamide
Journal Title: Cancer Cell
Volume: 28
Issue: 1
ISSN: 1535-6108
Publisher: Cell Press  
Date Published: 2015-07-13
Start Page: 15
End Page: 28
Language: English
DOI: 10.1016/j.ccell.2015.06.006
PROVIDER: scopus
PMCID: PMC4503933
PUBMED: 26175413
DOI/URL:
Notes: Export Date: 2 September 2015 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Alan H Shih
    59 Shih
  2. Raajit Kumar Rampal
    351 Rampal
  3. Ross Levine
    783 Levine
  4. Agnes Viale
    245 Viale
  5. Nicholas D Socci
    266 Socci
  6. Dmitry D. Pankov
    22 Pankov
  7. Richard O'Reilly
    748 O'Reilly
  8. Barbara Spitzer
    78 Spitzer
  9. Maria Kleppe
    41 Kleppe
  10. Kaitlyn Ruth Shank
    20 Shank
  11. Matthew D Keller
    26 Keller
  12. Sara Christina Meyer
    9 Meyer
  13. Jihae Ahn
    11 Ahn
  14. Ke   Xu
    11 Xu
  15. Sophia   Chiu
    6 Chiu